Luke Evnin - 16 Jan 2026 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Role
Director
Signature
/s/ Luke Evnin
Issuer symbol
HOWL
Transactions as of
16 Jan 2026
Net transactions value
-$20,942
Form type
4
Filing time
20 Jan 2026, 16:07:44 UTC
Previous filing
15 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
EVNIN LUKE Director C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON /s/ Luke Evnin 20 Jan 2026 0001134657

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HOWL Common Stock Sale $20,942 -38,782 -1.8% $0.5400 2,159,860 16 Jan 2026 See Footnotes F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
F2 The shares were sold as follows: 4,152 by MPM Asset Management LLC ("AM LLC"), 26,213 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,749 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 893 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,775 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.535 to $0.5495 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5 The shares are held as follows: 231,408 by AM LLC, 1,461,054 by BV 2014, 97,450 by BV 2014(B), 50,289 by AM BV2014 and 319,659 by MPM OIF.